Skip to content

SUTRO BIOPHARMA, INC.

STRO

CIK 0001382101

← back to feed
Revenue (TTM)
$105.36M
+65.2% YoY Q1 May 2026
Net Income (TTM)
−$182.81M
+16.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$12.83
+23.5% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-142.3%
Q1 May 2026
Net Margin
-173.5%
Q1 May 2026
Free Cash Flow (TTM)
−$237.43M
Q1 May 2026
Cash
$73.68M
Q1 May 2026
Total Debt
$4.06M
Q1 May 2026
Shares Outstanding
16.57M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings